Penumbra Inc
NYSE:PEN

Watchlist Manager
Penumbra Inc Logo
Penumbra Inc
NYSE:PEN
Watchlist
Price: 244.84 USD 1.81% Market Closed
Market Cap: 9.4B USD
Have any thoughts about
Penumbra Inc?
Write Note

Intrinsic Value

The intrinsic value of one PEN stock under the Base Case scenario is 106.95 USD. Compared to the current market price of 244.84 USD, Penumbra Inc is Overvalued by 56%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PEN Intrinsic Value
106.95 USD
Overvaluation 56%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Penumbra Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for PEN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about PEN?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Penumbra Inc

Provide an overview of the primary business activities
of Penumbra Inc.

What unique competitive advantages
does Penumbra Inc hold over its rivals?

What risks and challenges
does Penumbra Inc face in the near future?

Has there been any significant insider trading activity
in Penumbra Inc recently?

Summarize the latest earnings call
of Penumbra Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Penumbra Inc.

Provide P/S
for Penumbra Inc.

Provide P/E
for Penumbra Inc.

Provide P/OCF
for Penumbra Inc.

Provide P/FCFE
for Penumbra Inc.

Provide P/B
for Penumbra Inc.

Provide EV/S
for Penumbra Inc.

Provide EV/GP
for Penumbra Inc.

Provide EV/EBITDA
for Penumbra Inc.

Provide EV/EBIT
for Penumbra Inc.

Provide EV/OCF
for Penumbra Inc.

Provide EV/FCFF
for Penumbra Inc.

Provide EV/IC
for Penumbra Inc.

Show me price targets
for Penumbra Inc made by professional analysts.

What are the Revenue projections
for Penumbra Inc?

How accurate were the past Revenue estimates
for Penumbra Inc?

What are the Net Income projections
for Penumbra Inc?

How accurate were the past Net Income estimates
for Penumbra Inc?

What are the EPS projections
for Penumbra Inc?

How accurate were the past EPS estimates
for Penumbra Inc?

What are the EBIT projections
for Penumbra Inc?

How accurate were the past EBIT estimates
for Penumbra Inc?

Compare the revenue forecasts
for Penumbra Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Penumbra Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Penumbra Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Penumbra Inc compared to its peers.

Compare the P/E ratios
of Penumbra Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Penumbra Inc with its peers.

Analyze the financial leverage
of Penumbra Inc compared to its main competitors.

Show all profitability ratios
for Penumbra Inc.

Provide ROE
for Penumbra Inc.

Provide ROA
for Penumbra Inc.

Provide ROIC
for Penumbra Inc.

Provide ROCE
for Penumbra Inc.

Provide Gross Margin
for Penumbra Inc.

Provide Operating Margin
for Penumbra Inc.

Provide Net Margin
for Penumbra Inc.

Provide FCF Margin
for Penumbra Inc.

Show all solvency ratios
for Penumbra Inc.

Provide D/E Ratio
for Penumbra Inc.

Provide D/A Ratio
for Penumbra Inc.

Provide Interest Coverage Ratio
for Penumbra Inc.

Provide Altman Z-Score Ratio
for Penumbra Inc.

Provide Quick Ratio
for Penumbra Inc.

Provide Current Ratio
for Penumbra Inc.

Provide Cash Ratio
for Penumbra Inc.

What is the historical Revenue growth
over the last 5 years for Penumbra Inc?

What is the historical Net Income growth
over the last 5 years for Penumbra Inc?

What is the current Free Cash Flow
of Penumbra Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Penumbra Inc.

Business Breakdown

Penumbra Inc. is revolutionizing the landscape of medical technology with its innovative solutions tailored to treat some of the most challenging conditions in neuro and peripheral vascular health. Founded in 2004, the company has swiftly positioned itself as a leader in developing devices that empower physicians to provide advanced, minimally invasive treatment options. Penumbra's flagship products, including the Penumbra System for thrombectomy and its suite of neurovascular devices, showcase its commitment to enhancing patient outcomes and streamlining procedures. With a strong focus on research and development, the company aims to address unmet medical needs, thus facilitating its growth...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Penumbra Inc

Current Assets 891.8m
Cash & Short-Term Investments 291m
Receivables 176.1m
Other Current Assets 424.7m
Non-Current Assets 587.4m
PP&E 269.7m
Intangibles 173.3m
Other Non-Current Assets 144.4m
Current Liabilities 153.2m
Accounts Payable 33.2m
Accrued Liabilities 116.4m
Other Current Liabilities 3.6m
Non-Current Liabilities 221.7m
Long-Term Debt 22.2m
Other Non-Current Liabilities 199.4m
Efficiency

Earnings Waterfall
Penumbra Inc

Revenue
1.2B USD
Cost of Revenue
-399.2m USD
Gross Profit
764.6m USD
Operating Expenses
-652.8m USD
Operating Income
111.8m USD
Other Expenses
-77.3m USD
Net Income
34.5m USD

Free Cash Flow Analysis
Penumbra Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 2024, Penumbra reported $301 million in revenue, an 11.1% increase year-over-year, led by a 21.2% growth in its U.S. thrombectomy business. The launch of new products such as Lightning Flash 2.0 is driving this uptick. Gross margins improved to 66.5%, with expectations to exceed 70% within 18 to 24 months. Non-GAAP operating income rose to $40.3 million, reflecting efficient operations. Importantly, total revenue guidance for 2024 remains between $1.18 billion and $1.2 billion, while U.S. thrombectomy growth guidance is adjusted upwards to 24-25%. The company anticipates continued positive cash flow trends moving forward.

What is Earnings Call?
Fundamental Scores

PEN Profitability Score
Profitability Due Diligence

Penumbra Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
52/100
Profitability
Score

Penumbra Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

PEN Solvency Score
Solvency Due Diligence

Penumbra Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
87/100
Solvency
Score

Penumbra Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PEN Price Targets Summary
Penumbra Inc

Wall Street analysts forecast PEN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PEN is 238.8 USD with a low forecast of 191.9 USD and a high forecast of 273 USD.

Lowest
Price Target
191.9 USD
22% Downside
Average
Price Target
238.8 USD
2% Downside
Highest
Price Target
273 USD
12% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PEN?

Click here to dive deeper.

Dividends

Penumbra Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for PEN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

PEN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

PEN News

Other Videos

Profile

Penumbra Inc Logo
Penumbra Inc

Country

United States of America

Industry

Health Care

Market Cap

9.4B USD

Dividend Yield

0%

Description

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. The company is headquartered in Alameda, California and currently employs 3,800 full-time employees. The company went IPO on 2015-09-18. The firm designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. The company is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. The company is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. The company has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The firm's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, and Australia.

Contact

CALIFORNIA
Alameda
1 Penumbra
+15109952486.0
www.penumbrainc.com

IPO

2015-09-18

Employees

3 800

Officers

Co-Founder, Chairman, President & CEO
Mr. Adam Elsesser
Co-Founder & Director
Dr. Arani Bose M.D.
Chief Financial Officer
Ms. Maggie S. Yuen
Chief Accounting Officer
Mr. Lambert Shiu
Executive VP, General Counsel & Secretary
Ms. Johanna Roberts
Executive Vice President of Operations
Mr. Ben Sorci
Show More
Executive VP & Chief Information Officer
Mr. Pankaj Tiwari
Investor Relations Officer
Ms. Jee Hamlyn-Harris
Executive Vice President of Development & Compliance
Mr. Ben Tompkins
Executive VP & GM of Interventional
Ms. Shruthi Narayan
Show Less

See Also

Discover More
What is the Intrinsic Value of one PEN stock?

The intrinsic value of one PEN stock under the Base Case scenario is 106.95 USD.

Is PEN stock undervalued or overvalued?

Compared to the current market price of 244.84 USD, Penumbra Inc is Overvalued by 56%.

Back to Top